Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. sophomore Avg
|
New words:
abandonment, amnesty, band, Benelux, BIF, Cartel, commercializeReloxin, effort, Enhanced, entry, Ethicon, EUR, focused, framework, gastric, Johnson, Kita, launchedAlphagan, multiple, North, ofAlphagan®P, ofTazorac®andPrevage, opportunity, ourAlphagan®P, Pensionsand, presence, pursue, Quick, refund, relevant, reminder, responding, rest, retinoid, Round, SABG, scale, segregated, stockholder, sum, Swedish, Tazarotene, unchanged, Waldemar
Removed:
active, Acular, addressed, approve, binding, candidate, challenge, comply, consuming, coordinating, costly, creating, demonstrate, deny, depend, depending, disrupt, domestic, exclusion, exhibit, failure, improperly, inability, interpret, interruption, Italy, labeling, lead, lengthy, LS, managing, memantine, misused, ourAlphagan®Pproduct, phase, population, potentially, preclinical, produceBotox, profitability, profitable, publicity, qualify, raw, recall, refurbishment, rely, safe, seek, side, submit, suffer, supporting, taxable, technically, unanticipated, widespread, withdraw
Filing tables
Filing exhibits
Related press release
Allergan similar filings
Filing view
External links